Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium: A prospective, open-label, observational study

Drugs and Aging

Volumn 26, Issue 1, 2009, Pages 77-85

  Levin, Avi ^a   Ben Artzi, Moshe ^a   Beckerman, Pazit ^a   Haber, Guy ^a   Varon, David ^a   Ben Yehuda, Arie ^a   Muszkat, Mordechai ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Elderly; Enoxaparin sodium, therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; ENOXAPARIN; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; ELDERLY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; INJECTION SITE BLEEDING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BODY WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; FEMALE; HEMORRHAGE; HUMANS; INPATIENTS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TICLOPIDINE; TREATMENT OUTCOME; WARFARIN;

EID: 58149105381     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926010-00006     Document Type: Article

References (37)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 Jan; 119 (1 Suppl.): 64S-94S
2. Braunwald E, Antman E, Beasley J, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2000; 36: 970-1062
3. Bertrand M, Simoons M, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J 2002; 23: 1809-40
4. Levine M, Jent M, Hirsh J, et al. A comparison of low molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81
5. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109 (8): 997-1003
6. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355 (10): 1006-17
7. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474-82
8. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41 (1): 8-14
9. Macie C, Forbes L, Foster GA, et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004; 125: 1616-21
10. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002; 72 (3): 308-18
11. Hulot JS, Montalescot G, Lechat P, et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-52
12. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143 (5): 753-9
13. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144 (9): 673-84
14. Food and Drug Administration. Enoxaparin injection drug approval: 2004 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2004/ lovenox_PI.pdf. [Accessed 2005 May 6]
15. Lacy CF, Armstrong LL. Drug information handbook. 16th ed. Hudson (OH): Lexi-comp, Inc., 2007
16. Enoxaparin sodium investigator brochure. 12th ed. Bridgewater (NJ): Aventis Pharma, 2003
17. Henderson MC, White RH. Anticoagulation in the elderly. Curr Opin Pulm Med 2001; 7 (5): 365-70
18. Clinch D, Banerjee AK, Ostick G. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984; 13 (2): 120-3
19. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110 (4): 392-8
20. Antman EM, Morrow DA, McCabe CH, et al. ExTRACT-TIMI 25 investigators: enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354 (14): 1477-88
21. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004 Oct; 148 (4): 582-9
22. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56 (1): 96-103
23. Ellis SG, Elliott J, Horrigan M, et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996; 78 (6): 642-6
24. Barba R, Marco J, Martin-Alvarez H, et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005; 3 (5): 856-62
25. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294 (24): 3108-16
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
27. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2000; 36: 970-1062
28. Thavendiranathan P, Bagai A, Ebidia A, et al. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med 2005 Jun; 20 (6): 520-4
29. Teien AN, Abildgaard U, Hook M. The anticoagulant effect of heparan sulfate and dermatan sulfate. Thromb Res 1976; 8 (6): 859-67
30. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103 (5): 658-63
31. Wedick NM, Barrett-Connor E, Knoke JD, et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. J Am Geriatr Soc 2002; 50 (11): 1810-5
32. Newman AB, Yanez D, Harris T, et al. Weight change in old age and its association with mortality. J Am Geriatr Soc 2001; 49 (10): 1309-18
33. Covinsky KE, Martin GE, Beyth RJ, et al. The relationship between clinical assessments of nutritional status and adverse outcomes in older hospitalized medical patients. J Am Geriatr Soc 1999; 47 (5): 532-8
34. Maurer MS, Luchsinger JA, Wellner R, et al. The effect of body mass index on complications from cardiac surgery in the oldest old. J Am Geriatr Soc 2002; 50 (6): 988-94
35. Monreal M, Falgá C, Valle R, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006 Dec; 119 (12): 1073-9
36. Cook LM, Kahn SR, Goodwin J, et al. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007 May; 5 (5): 937-41
37. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001 Feb 6; 134 (3): 191-202